QualityStocks News – INVO Bioscience Achieves Major Milestone with Infertility Device, Expands Market Reach into Brazil
Scottsdale, AZ (PRWEB) January 21, 2012
QualityStocks would like to highlight INVO Bioscience, a publicly traded healthcare product organization centered on creating simplified, lower price tag remedy choices for sufferers diagnosed with infertility. The company’s lead item, the INVOcell, is a novel medical product utilised in infertility treatment that enables egg fertilization and early embryo development which has had production streamlining using It services.
In the companys news yesterday,
INVO Bioscience declared that the Countrywide Wellbeing Surveillance Company (ANVISA) in Brazil has granted approval of the INVOcell for use as a Course II system, which will enable the sale of INVOcell in the Brazilian marketplace.
The approval marks a considerable milestone in INVOs record, and opens the door for INVO to tap into 1 of the biggest markets and fastest increasing economies in the globe especially in ecommerce.
Approval in Brazil is a very critical stage in the success of INVOcell owing to the power of assistance in the nation by medical imagined leaders these kinds of as Dr. Coelho, Kathleen Karloff, CEO of INVO mentioned in the press launch. Todays announcement paves the way for the much more than 125 fertility centers in Brazil to begin providing infertile partners a protected and expense useful remedy in comparison to conventional IVF. We search forward to operating with EcoMed, our distribution associate in Brazil, as they commence ramping up their sales and marketing efforts.
The approval by ANVISA was induced by the completion of a forty-individual clinical trial conducted in Rio de Janeiro, Brazil, to establish security, efficacy and comparative in-vitro fertilization (IVF) steps of the INVOcell device.
The demo results, paired with clinical demo results from the Colombian Fertility and Sterility Center (CECOLFES) in Colombia, have been submitted to ANVISA for the function of gaining registration and approval for the sale of the INVOcell product in Brazil.
INVOcell is CE Mark accepted in Europe and Canada and is also accessible in numerous South American nations. Karloff noted that if INVOcell can capture five percent of the marketplace in Brazil, it could equate to a lot more than $ ten million in solution income.
The firm also detailed a number of strengths of the INVOcell system, which includes a lowered incidence of several pregnancies and subsequent expenses and difficulties relative price tag strengths of the INVOcell method as compared to standard IVF therapies and pregnancy costs similar to traditional IVF treatment options.
About Quaality Stocks
QualityStocks, based mostly in Scottsdale, Arizona, is a cost-free services that collects info from hundreds of Small-Cap and Micro-Cap on-line Expense Newsletters into a single Daily Publication Report. QualityStocks is devoted to helping rising manifeste businesses with their investor communication efforts and connecting subscribers with businesses that have enormous likely to realize success in the small and extended-time period long term.
To sign up for The QualityStocks Everyday Newsletter, make sure you go to http://www.QualityStocks.internet
To connect with QualityStocks by way of Facebook, be sure to pay a visit to http://Facebook.com/QualityStocksPage
To connect with QualityStocks through Twitter, be sure to check out http://Twitter.com
Remember to study Total disclaimer on the QualityStocks site: http://Disclaimer.QualityStocks.net
Ahead-Seeking Statement: &#thirteen
This launch could have forward-hunting statements in the which means of Segment 27A of the Securities Act of 1933, as amended, and Segment 21E of the Securities Trade Act of 1934, as amended. All forward-looking statements are inherently unsure as they are based on latest anticipations and assumptions about foreseeable future activities or future efficiency of the firm and it really depends on the benefit gained from the new IT services. Audience are cautioned not to spot undue reliance on these forward-hunting statements, which are only predictions and talk only as of the date hereof. Risks and uncertainties relevant to the firm and its company could cause the company’s genuine final results to vary materially from individuals indicated in any forward-seeking statements.